Public Profile

MorphoSys

MorphoSys AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its innovative approach in the field of therapeutic antibodies. Founded in 1992, the company has made significant strides in the development of treatments for cancer and autoimmune diseases, establishing a strong presence in Europe and North America. With a focus on proprietary and partnered drug development, MorphoSys has achieved notable milestones, including the successful launch of its flagship product, Monjuvi (tafasitamab), which targets specific forms of lymphoma. The company’s unique technology platforms, such as its Ylanthus® antibody library, enable the rapid discovery of high-quality therapeutic candidates, positioning MorphoSys as a key player in the biopharmaceutical industry. Through its commitment to advancing healthcare, MorphoSys continues to make impactful contributions to patient care and treatment options.

DitchCarbon Score

How does MorphoSys's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

36

Industry Average

Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

25

Industry Benchmark

MorphoSys's score of 36 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.

92%

MorphoSys's reported carbon emissions

In 2023, MorphoSys reported total carbon emissions of approximately 18,856,470 kg CO2e. This figure includes 101,820 kg CO2e from Scope 1 emissions, 1,340 kg CO2e from Scope 2 emissions (market-based), and a significant 18,753,310 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by capital goods (10,204,310 kg CO2e) and business travel (1,833,700 kg CO2e). In comparison, the 2022 emissions totalled about 2,236,960 kg CO2e, with Scope 1 emissions at 103,350 kg CO2e, Scope 2 at 1,060,640 kg CO2e, and Scope 3 at 1,072,960 kg CO2e. This indicates a substantial increase in emissions from 2022 to 2023. Despite the lack of specific reduction targets or initiatives disclosed, MorphoSys is actively monitoring its carbon footprint across all scopes. The company’s commitment to addressing climate change is evident, although further details on specific reduction strategies or targets are not available.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
103,350
000,000
Scope 2
1,060,640
0,000
Scope 3
1,072,960
00,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. MorphoSys's primary industry is Other business services (74), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. MorphoSys is headquartered in DE, which has a rank of medium, indicating medium grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

MorphoSys is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Molecular Partners AG

CH
Health and social work services (85)
Updated 4 days ago

Almirall

ES
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Consort Medical plc

GB
Health and social work services (85)
Updated about 6 hours ago

Gilead Sciences

US
Research and development services (73)
Updated 4 days ago

Zealand Pharma A/S

DK
Health and social work services (85)
Updated 4 days ago

Incyte

US
Health and social work services (85)
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers